Epidermolysis Bullosa - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 59 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Epidermolysis Bullosa - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Epidermolysis Bullosa - Pipeline Review, H2 2014', provides an overview of the Epidermolysis Bullosa's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Epidermolysis Bullosa and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Epidermolysis Bullosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epidermolysis Bullosa pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Epidermolysis Bullosa Overview 7
Therapeutics Development 8
Pipeline Products for Epidermolysis Bullosa - Overview 8
Pipeline Products for Epidermolysis Bullosa - Comparative Analysis 9
Epidermolysis Bullosa - Therapeutics under Development by Companies 10
Epidermolysis Bullosa - Therapeutics under Investigation by Universities/Institutes 11
Epidermolysis Bullosa - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Epidermolysis Bullosa - Products under Development by Companies 15
Epidermolysis Bullosa - Products under Investigation by Universities/Institutes 16
Epidermolysis Bullosa - Companies Involved in Therapeutics Development 17
RegeneRx Biopharmaceuticals, Inc. 17
Kings College London 18
Fibrocell Science, Inc. 19
Birken AG 20
TWi Pharmaceuticals, Inc. 21
Scioderm, Inc. 22
Epidermolysis Bullosa - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
SD-101 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
RGN-137 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ICX-RHY - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
OleogelS-10 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Stem Cell Therapy for Epidermolysis Bullosa - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AC-201 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Sulforaphane - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Gene Therapy for Epidermolysis Bullosa - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Gene Modified Autologous Fibroblast Cell Therapy - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Gene Therapy for Epidermolysis Bullosa - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Epidermolysis Bullosa - Recent Pipeline Updates 45
Epidermolysis Bullosa - Dormant Projects 49
Epidermolysis Bullosa - Discontinued Products 50
Epidermolysis Bullosa - Product Development Milestones 51
Featured News & Press Releases 51
Sep 09, 2014: Scioderm to Present Data from Phase 2b Study of Zorblisa (SD-101) at the debra International Congress 51
Jul 23, 2014: Fibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy Group 51
Jun 13, 2014: Fibrocell Science Receives Orphan Drug Designation for Genetically-Modified Autologous Human Fibroblasts to Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB) 52
May 28, 2014: Fibrocell Science Announces Plans for Process Development and Manufacturing of Genetically-modified Cell Therapy for Rare Disease, RDEB 52
Apr 01, 2014: Scioderm Completes Enrollment of Phase 2b Study of SD-101, a Novel Topical Therapy for Patients with Epidermolysis Bullosa 53
Jan 22, 2014: Scioderm, Inc. Receives Orphan Drug Designation in the European Union for Novel Topical Therapy to Treat Epidermolysis Bullosa 54
Jan 06, 2014: Scioderm Initiates Phase 2B Study of SD-101, A Novel Topical Therapy, for Patients with Epidermolysis Bullosa 54
Dec 17, 2013: Scioderm receives Positive Opinion from European Orphan Medicinal Products Committee for Novel Topical Therapy to Treat Epidermolysis Bullosa 55
Jun 24, 2013: RegeneRx Announces Results Of Phase II Clinical Trial On Patients With Epidermolysis Bullosa 56
Apr 29, 2013: Scioderm's SD-101 Receives Breakthrough Therapy Designation From FDA For Treatment Of Epidermolysis Bullosa 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products under Development for Epidermolysis Bullosa, H2 2014 8
Number of Products under Development for Epidermolysis Bullosa - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2014 17
Epidermolysis Bullosa - Pipeline by Kings College London., H2 2014 18
Epidermolysis Bullosa - Pipeline by Fibrocell Science, Inc., H2 2014 19
Epidermolysis Bullosa - Pipeline by Birken AG, H2 2014 20
Epidermolysis Bullosa - Pipeline by TWi Pharmaceuticals, Inc., H2 2014 21
Epidermolysis Bullosa - Pipeline by Scioderm, Inc., H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Epidermolysis Bullosa Therapeutics - Recent Pipeline Updates, H2 2014 45
Epidermolysis Bullosa - Dormant Projects, H2 2014 49
Epidermolysis Bullosa - Discontinued Products, H2 2014 50